Is LAIV Dead or Just on LAIV-Support?

Very recently we came across several studies in which small differences in design had a major impact on outcomes. A blog is not a good place to dig deeply into the minutiae of study design as the discussion becomes quickly very dry and quite technical. However, readers Continue reading Is LAIV Dead or Just on LAIV-Support?

There is Momentum Building for RSV Therapeutics

Sometimes – for no obvious reason – there is a flurry of publications from a particular area which has been quiet for a long time.  RSV is such an area where new drug development had a hard time getting started.  Continue reading There is Momentum Building for RSV Therapeutics

Aerosolized Antibiotics & Selling Nebulizers

“The medicine comes for free, just pay us for the inhaler” should be the marketing slogan for this group of therapeutics.  Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to ‘evergreen’ off-patent Continue reading Aerosolized Antibiotics & Selling Nebulizers

Following The Publication Trail of Two RSV Drugs

In a publication from 2007, investigators from Arrow Pharmaceuticals told us that A-60444 (later renamed to RSV-604) was already in Phase 2.  Since then, it has been very quiet about this compound.  Some have suggested that Novartis has stopped development [1], Continue reading Following The Publication Trail of Two RSV Drugs